Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Director | June 23, 2026 | June 25, 2026 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director · President & CEO | February 19, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,712 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Exercise / conversion · Acquired 4,712 · Balance 11,712 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Exercise / conversion · Disposed 4,712 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units are fully vested. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,324 |
Reported balance
After 2026-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-24 · Grant · Acquired 2,324 · Balance 2,324 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.55 · Expires 2036-06-23 | Direct | 3,691 |
Reported balance
After 2026-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-24 · Grant · Acquired 3,691 · Balance 3,691 F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units are fully vested. The restricted stock units have no expiration date.
F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.
F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
Trevi Therapeutics, Inc.
Report date February 19, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2036-02-18 | Direct | 675,000 |
Reported balance
After 2026-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 675,000 · Balance 675,000 F1: This option was granted on February 19, 2026. The 675,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 19, 2026. The 675,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
JUNIPER PHARMACEUTICALS INC
Report date August 14, 2018 · Filed August 15, 2018
Section 16 reporting ended · disclosed 2018-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 1
1 source rowRow 1 · 2018-08-14 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2: Includes 15,000 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 15,000 restricted stock units was cancelled in exchange for the Offer Price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
F2: Includes 15,000 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 15,000 restricted stock units was cancelled in exchange for the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 22:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 2,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · derivative · entry 4 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,324 Underlying: Common Stock · 2,324 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 22:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 3,691 | $0.00 Strike: $107.55 | $0.00 |
DisclosureSEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · derivative · entry 3 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,691 Underlying: Common Stock · 3,691 shares Expires 2036-06-23 F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 22:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · derivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units are fully vested. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units are fully vested. The restricted stock units have no expiration date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 22:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,712 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · nonDerivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:16 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 675,000 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001193125-26-061391 · ownership.xml · derivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: This option was granted on February 19, 2026. The 675,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 4,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-063076 · tm2519230-6_4seq1.xml · derivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,712 Underlying: Common Stock · 4,712 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 7,037 | $0.00 Strike: $63.66 | $0.00 |
DisclosureSEC source: 0001104659-25-063076 · tm2519230-6_4seq1.xml · derivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,037 Underlying: Common Stock · 7,037 shares Expires 2035-06-23 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061712 · tm2518591-5_4seq1.xml · derivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-061712 · tm2518591-5_4seq1.xml · nonDerivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 31, 2025 Filed Jun 3, 2025 20:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantPerformance Stock Option (right to buy) · Derivative | 102,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000950170-25-080883 · ownership.xml · derivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,400 Underlying: Common Stock · 102,000 shares Expires 2034-02-14 F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 170,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 54,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 102,000 shares of common stock. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:30 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 5,263 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950170-25-044436 · ownership.xml · derivative · entry 3 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,263 shares Expires 2025-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on May 15, 2015. The 5,263 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:30 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 5,263 | $6.58 | $34,624.75 |
DisclosureSEC source: 0000950170-25-044436 · ownership.xml · nonDerivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,313 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.55 to $6.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:30 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 5,263 | $1.43 | $7,526.09 |
DisclosureSEC source: 0000950170-25-044436 · ownership.xml · nonDerivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantPerformance Stock Option (right to buy) · Derivative | 54,400 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000950170-25-037886 · ownership.xml · derivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,400 Underlying: Common Stock · 54,400 shares Expires 2034-02-14 F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 170,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 54,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 811,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0000950170-25-024110 · ownership.xml · derivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 811,000 Underlying: Common Stock · 811,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 811,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 7,501 | $0.00 Strike: $18.99 | $0.00 |
DisclosureSEC source: 0001104659-24-101365 · tm2424408-1_4seq1.xml · derivative · entry 7 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,501 shares Expires 2031-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 9,250 | $0.00 Strike: $21.37 | $0.00 |
DisclosureSEC source: 0001104659-24-101365 · tm2424408-1_4seq1.xml · derivative · entry 6 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-24-101365 · tm2424408-1_4seq1.xml · derivative · entry 5 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 31,751 | $52.40 | $1,663,803.20 |
DisclosureSEC source: 0001104659-24-101365 · tm2424408-1_4seq1.xml · nonDerivative · entry 4 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 22, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $52.00 to $53.00. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 7,501 | $18.99 | $142,443.99 |
DisclosureSEC source: 0001104659-24-101365 · tm2424408-1_4seq1.xml · nonDerivative · entry 3 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 9,250 | $21.37 | $197,672.50 |
DisclosureSEC source: 0001104659-24-101365 · tm2424408-1_4seq1.xml · nonDerivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 15,000 | $22.93 | $343,950.00 |
DisclosureSEC source: 0001104659-24-101365 · tm2424408-1_4seq1.xml · nonDerivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2024 Filed Sep 9, 2024 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 1,840 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950170-24-104804 · ownership.xml · derivative · entry 6 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,840 shares Expires 2024-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018. Read SEC document |
| September 09, 2024 Filed Sep 9, 2024 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 1,840 | $3.04 | $5,586.61 |
DisclosureSEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 4 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,313 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.010 to $3.085 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 09, 2024 Filed Sep 9, 2024 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 1,840 | $1.43 | $2,631.20 |
DisclosureSEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 3 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 18,300 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · derivative · entry 9 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,300 shares Expires 2032-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 1,736 | $0.00 Strike: $18.99 | $0.00 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · derivative · entry 8 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,501 Underlying: Common Stock · 1,736 shares Expires 2031-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 4,305 | $0.00 Strike: $21.37 | $0.00 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · derivative · entry 7 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 4,305 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 12,900 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · derivative · entry 6 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 12,900 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 37,241 | $50.45 | $1,878,700.45 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · nonDerivative · entry 5 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 22, 2024. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.99. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 18,300 | $4.15 | $75,945.00 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · nonDerivative · entry 4 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,736 | $18.99 | $32,966.64 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · nonDerivative · entry 3 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,305 | $21.37 | $91,997.85 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · nonDerivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 12,900 | $22.93 | $295,797.00 |
DisclosureSEC source: 0001104659-24-098941 · tm2423816-1_4seq1.xml · nonDerivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 4,219 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950170-24-104804 · ownership.xml · derivative · entry 5 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,840 Underlying: Common Stock · 4,219 shares Expires 2024-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 4,219 | $3.03 | $12,784.41 |
DisclosureSEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,313 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 21:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 4,219 | $1.43 | $6,033.17 |
DisclosureSEC source: 0000950170-24-104804 · ownership.xml · nonDerivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 40,277 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · derivative · entry 9 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,059 Underlying: Common Stock · 40,277 shares Expires 2024-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 40,277 | $3.11 | $125,309.80 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 6 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,313 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 40,277 | $1.43 | $57,596.11 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 5 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 10,981 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · derivative · entry 8 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,336 Underlying: Common Stock · 10,981 shares Expires 2024-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 10,981 | $3.02 | $33,205.45 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 4 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,313 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.02 to $3.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 10,981 | $1.43 | $15,702.83 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 3 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 3,863 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · derivative · entry 7 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,317 Underlying: Common Stock · 3,863 shares Expires 2024-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 3,863 | $3.02 | $11,677.46 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 2 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,313 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.01 to $3.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:54 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 3,863 | $1.43 | $5,524.09 |
DisclosureSEC source: 0000950170-24-104061 · ownership.xml · nonDerivative · entry 1 GOOD JENNIFER L · CIK 0001229245 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001104659-24-094009 · tm2422915-1_4seq1.xml · derivative · entry 9 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,300 Underlying: Common Stock · 1,700 shares Expires 2032-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 5,763 | $0.00 Strike: $18.99 | $0.00 |
DisclosureSEC source: 0001104659-24-094009 · tm2422915-1_4seq1.xml · derivative · entry 8 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,237 Underlying: Common Stock · 5,763 shares Expires 2031-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 4,945 | $0.00 Strike: $21.37 | $0.00 |
DisclosureSEC source: 0001104659-24-094009 · tm2422915-1_4seq1.xml · derivative · entry 7 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,555 Underlying: Common Stock · 4,945 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 2,100 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0001104659-24-094009 · tm2422915-1_4seq1.xml · derivative · entry 6 GOOD JENNIFER L · CIK 0001229245 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,900 Underlying: Common Stock · 2,100 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.